Abstract 1804P
Background
Small cell lung cancer（SCLC） is a malignant, aggressive and rapidly progressing cancer. There is no standard treatment strategy for patients with advanced SCLC who experienced progression with first line of chemotherapy. Apatinib, an oral tyrosine kinaese inhibitor targeting vascular endothelial growth receptor 2 (VEGFR 2), has shown well anti-tumor activity and manageable toxicities in SCLC. Some previous cases showed that apatinib plus topotecan for laterline therapy for advanced SCLC patients is safe and effective, but there is no similar studies at home and abroad.
Methods
Our study retrospectively assessed the efficacy and safety of apatinib plus topotecan in patients with advanced SCLC after the first line of chemotherapy. The primary endpoint was progression free survival (PFS) and overall survival (OS). The study was expected to enroll 14 patients who received apatinib (250mg QD) plus topotecan (2mg QD; day1-5, every four weeks). Treatment was continued until disease progression and the tumor response was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. The tocxicity was determined according to CTCAE 4.0.
Results
Between January 2017 and April 2020, 14 advanced SCLC patients was recruited. The PFS and OS from the start treatment of apatinib plus topotecan were evaluated. Based on the Kaplan-Meier estimation and log-rank test, the median PFS was 15.8 weeks (95%CI, 8.833–22.767), whereas the median OS was 33 weeks (95%CI, 30.25–35.75).
Conclusions
Apatinib plus topotecan exhibits superior activity and generally manageable toxicities for the pretreated patients with advanced small cell lung cancer. It may provide a new therapy strategy for them, but large sample and additional clinical trials are also needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.